Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,changeToLiabilities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,shortName,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,exchangeDataDelayedBy,priceHint,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,M3V.DE,17825165,1820000,,,1229075,,1207825,133500,1815693,1221166,1221166,429118,-27,,,,21250,4040078,2818912,2224385,7910,,1207825,1207825,855,11461332,6560341,17826020,1058844,24386363,1820000,255247,4544688,4780443,16274753,4067324,1779898,160682,7638031,312042,3315460,21536,0,5858133,en-US,US,EQUITY,False,Delayed Quote,EUR,MEVIS MEDICAL SOL.NA O.N.,0.013239362,60424000,3.3894844,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,2,33.2,1630510581,0.0,34.0,34.0,33.2,249,GER,de_market,0.0,33.2 - 34.0,33.2,32.8,33.6,600,600,finmb_38777177,XETRA,MeVis Medical Solutions AG,EUR,61,181,3.2000008,0.10666669,30.0 - 35.6,-2.3999977,-0.06741567,30.0,35.6,1622097000,1622097000,1622097000,0.04,11.756374,0.0012048192,2.824,9.795,33.30857,-0.1085701,-0.0032595245,32.766197,0.43380356,0.25,,,35.6,30.0,33.31,32.77,61,181,1.82M,,479.39k,73.65%,16.94%,,,,,,0.95,2.88%,0.04,0.12%,,33.64%,,"Jun 25, 2020",,,"Sep 30, 2020","Mar 31, 2021",31.08%,32.34%,13.57%,28.83%,16.53M,9.09,-6.90%,7.95M,5.47M,5.14M,2.82,-18.90%,4.07M,2.23,,,4.29,9.80,,,Value,28359,Healthcare,104,"MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",Bremen,49 421 22495 0,1577750400,Germany,http://www.mevis.de,86400,Caroline-Herschel-Strasse 1,49 421 22495 999,Health Information Services
t-1,M3V.DE,17825165,1820000,,,1229075,,1207825,133500,1815693,1221166,1221166,429118,-27,,,,21250,4040078,2818912,2224385,7910,,1207825,1207825,855,11461332,6560341,17826020,1058844,24386363,1820000,255247,4544688,4780443,16274753,4067324,1779898,160682,7638031,312042,3315460,21536,0,5858133,en-US,US,EQUITY,False,Delayed Quote,EUR,MEVIS MEDICAL SOL.NA O.N.,0.013239362,60424000,3.3894844,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,2,33.2,1630510581,0.0,34.0,34.0,33.2,249,GER,de_market,0.0,33.2 - 34.0,33.2,32.8,33.6,600,600,finmb_38777177,XETRA,MeVis Medical Solutions AG,EUR,61,181,3.2000008,0.10666669,30.0 - 35.6,-2.3999977,-0.06741567,30.0,35.6,1622097000,1622097000,1622097000,0.04,11.756374,0.0012048192,2.824,9.795,33.30857,-0.1085701,-0.0032595245,32.766197,0.43380356,0.25,,,35.6,30.0,33.31,32.77,61,181,1.82M,,479.39k,73.65%,16.94%,,,,,,0.95,2.88%,0.04,0.12%,,33.64%,,"Jun 25, 2020",,,"Sep 30, 2020","Mar 31, 2021",31.08%,32.34%,13.57%,28.83%,16.53M,9.09,-6.90%,7.95M,5.47M,5.14M,2.82,-18.90%,4.07M,2.23,,,4.29,9.80,,,Value,28359,Healthcare,104,"MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",Bremen,49 421 22495 0,1577750400,Germany,http://www.mevis.de,86400,Caroline-Herschel-Strasse 1,49 421 22495 999,Health Information Services
t-2,M3V.DE,17823594,1820000,,,1386258,,1362020,85500,1970186,1452331,1452331,395452,-27,,,,24238,4226936,2774605,2256751,-66073,,1362020,1362020,2426,11461332,9964821,17826020,917000,27790843,1820000,283593,4544688,6176088,16273539,3953630,3788733,194358,11008478,312042,6771255,92744,0,7219745,en-US,US,EQUITY,False,Delayed Quote,EUR,MEVIS MEDICAL SOL.NA O.N.,0.013239362,60424000,3.3894844,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,2,33.2,1630510581,0.0,34.0,34.0,33.2,249,GER,de_market,0.0,33.2 - 34.0,33.2,32.8,33.6,600,600,finmb_38777177,XETRA,MeVis Medical Solutions AG,EUR,61,181,3.2000008,0.10666669,30.0 - 35.6,-2.3999977,-0.06741567,30.0,35.6,1622097000,1622097000,1622097000,0.04,11.756374,0.0012048192,2.824,9.795,33.30857,-0.1085701,-0.0032595245,32.766197,0.43380356,0.25,,,35.6,30.0,33.31,32.77,61,181,1.82M,,479.39k,73.65%,16.94%,,,,,,0.95,2.88%,0.04,0.12%,,33.64%,,"Jun 25, 2020",,,"Sep 30, 2020","Mar 31, 2021",31.08%,32.34%,13.57%,28.83%,16.53M,9.09,-6.90%,7.95M,5.47M,5.14M,2.82,-18.90%,4.07M,2.23,,,4.29,9.80,,,Value,28359,Healthcare,104,"MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",Bremen,49 421 22495 0,1577750400,Germany,http://www.mevis.de,86400,Caroline-Herschel-Strasse 1,49 421 22495 999,Health Information Services
t-3,M3V.DE,17823594,1820000,,,1386258,,1362020,85500,1970186,1452331,1452331,395452,-27,,,,24238,4226936,2774605,2256751,-66073,,1362020,1362020,2426,11461332,9964821,17826020,917000,27790843,1820000,283593,4544688,6176088,16273539,3953630,3788733,194358,11008478,312042,6771255,92744,0,7219745,en-US,US,EQUITY,False,Delayed Quote,EUR,MEVIS MEDICAL SOL.NA O.N.,0.013239362,60424000,3.3894844,15,Europe/Berlin,CEST,7200000,False,False,REGULAR,0,2,33.2,1630510581,0.0,34.0,34.0,33.2,249,GER,de_market,0.0,33.2 - 34.0,33.2,32.8,33.6,600,600,finmb_38777177,XETRA,MeVis Medical Solutions AG,EUR,61,181,3.2000008,0.10666669,30.0 - 35.6,-2.3999977,-0.06741567,30.0,35.6,1622097000,1622097000,1622097000,0.04,11.756374,0.0012048192,2.824,9.795,33.30857,-0.1085701,-0.0032595245,32.766197,0.43380356,0.25,,,35.6,30.0,33.31,32.77,61,181,1.82M,,479.39k,73.65%,16.94%,,,,,,0.95,2.88%,0.04,0.12%,,33.64%,,"Jun 25, 2020",,,"Sep 30, 2020","Mar 31, 2021",31.08%,32.34%,13.57%,28.83%,16.53M,9.09,-6.90%,7.95M,5.47M,5.14M,2.82,-18.90%,4.07M,2.23,,,4.29,9.80,,,Value,28359,Healthcare,104,"MeVis Medical Solutions AG develops, markets, and sells software for analyzing and evaluating image data to equipment manufacturers of medical devices and providers of medical IT platforms in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, prostate, and colon cancers, as well as neurological disorders. It operates in two segments, Digital Mammography and Other Diagnostics. The Digital Mammography segment develops and markets software products, which support breast diagnostic imaging and intervention. This segment also offers software applications for digital mammography, such as ultrasound, magnetic resonance imaging, and tomosynthesis. The Other Diagnostics segment provides digital radiology products, including magnetic resonance imaging and computer tomography for diseases, such as lung, prostate, and intestinal disorders, as well as general image-based analysis and diagnostics of radiology images. Its services are also used for lung diagnostics and general analysis of MR-image data; and technical visualization, which are used in training, for publication, presentations, and research purposes. This segment also provides interactive online training to enhance the diagnostic capabilities of clinical end customers. The company was founded in 1992 and is based in Bremen, Germany. MeVis Medical Solutions AG operates as a subsidiary of Varex Imaging Deutschland AG.",Bremen,49 421 22495 0,1577750400,Germany,http://www.mevis.de,86400,Caroline-Herschel-Strasse 1,49 421 22495 999,Health Information Services
